Medicare Eases ESRD Bundled Payment Cuts Derived From Reduced Drug Use
This article was originally published in The Pink Sheet Daily
In a final rule, CMS agrees with public commenters that treatment access could be disrupted by payment cuts mandated due to reduced drug utilization. Remedies include payment offsets and a policy phase-in so that the current bundled rate will be essentially intact through 2015.
You may also be interested in...
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.
FDA/CMS Summit speakers say they've yet to see any real interest from manufacturers in putting money at risk if their products don't meet outcome measures.